JP2006501295A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501295A5
JP2006501295A5 JP2004540932A JP2004540932A JP2006501295A5 JP 2006501295 A5 JP2006501295 A5 JP 2006501295A5 JP 2004540932 A JP2004540932 A JP 2004540932A JP 2004540932 A JP2004540932 A JP 2004540932A JP 2006501295 A5 JP2006501295 A5 JP 2006501295A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
compound according
halogen
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004540932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501295A (ja
JP4653486B2 (ja
Filing date
Publication date
Priority claimed from GBGB0223038.1A external-priority patent/GB0223038D0/en
Application filed filed Critical
Publication of JP2006501295A publication Critical patent/JP2006501295A/ja
Publication of JP2006501295A5 publication Critical patent/JP2006501295A5/ja
Application granted granted Critical
Publication of JP4653486B2 publication Critical patent/JP4653486B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004540932A 2002-10-04 2003-09-25 ガンマ−セクレターゼ阻害剤としてのシクロヘキシルスルホン Expired - Fee Related JP4653486B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223038.1A GB0223038D0 (en) 2002-10-04 2002-10-04 Therapeutic compounds
PCT/GB2003/004196 WO2004031139A1 (en) 2002-10-04 2003-09-25 Cyclohexyl sulphones as gamma-secretase inhibitors

Publications (3)

Publication Number Publication Date
JP2006501295A JP2006501295A (ja) 2006-01-12
JP2006501295A5 true JP2006501295A5 (https=) 2006-11-02
JP4653486B2 JP4653486B2 (ja) 2011-03-16

Family

ID=9945312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004540932A Expired - Fee Related JP4653486B2 (ja) 2002-10-04 2003-09-25 ガンマ−セクレターゼ阻害剤としてのシクロヘキシルスルホン

Country Status (9)

Country Link
US (1) US6890956B2 (https=)
EP (1) EP1551799B1 (https=)
JP (1) JP4653486B2 (https=)
AT (1) ATE464287T1 (https=)
AU (1) AU2003269211C1 (https=)
CA (1) CA2500969A1 (https=)
DE (1) DE60332137D1 (https=)
GB (1) GB0223038D0 (https=)
WO (1) WO2004031139A1 (https=)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
WO2003032994A2 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
GB0323258D0 (en) * 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
RU2006144075A (ru) * 2004-06-16 2008-07-27 Вайет (Us) ДИФЕНИЛИМИДАЗОПИРИМИДИН И -ИМИДАЗОЛАМИНЫ КАК ИНГИБИТОРЫ β-СЕКРЕТАЗЫ
CA2593515A1 (en) * 2005-01-14 2006-07-20 Wyeth Amino-imidazolones for the inhibition of beta-secretase
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
US20090215775A1 (en) * 2005-05-17 2009-08-27 Huw David Lewis Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
GB0513747D0 (en) * 2005-07-06 2005-08-10 Merck Sharp & Dohme Therapeutic compounds
WO2007103114A2 (en) 2006-03-07 2007-09-13 The Brigham & Women's Hospital, Inc. Notch inhibition in the treatment or prevention of atherosclerosis
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8377886B2 (en) * 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
EP2273877B1 (en) * 2008-04-23 2014-04-16 Merck Sharp & Dohme Corp. Cyclobutyl sulfones as notch sparing gamma secretase inhibitors
AU2009316264B2 (en) 2008-11-24 2016-09-15 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
WO2010090954A1 (en) * 2009-02-06 2010-08-12 Merck Sharp & Dohme Corp. Novel trifluoromethylsulfonamide gamma secretase inhibitor
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20120129189A1 (en) * 2009-07-17 2012-05-24 Chulan Kwon Methods of Controlling Cell Proliferation
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
CN102762534A (zh) * 2009-09-18 2012-10-31 扎里卡斯药品有限公司 作为钙通道阻断剂的芳基砜衍生物
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US9629891B2 (en) 2011-10-17 2017-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015104343A1 (en) * 2014-01-09 2015-07-16 Proyecto De Biomedicina Cima, S.L. New antifibrinolytic compounds
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2017019496A1 (en) 2015-07-24 2017-02-02 Berenson James Richard Gamma secretase modulators for the treatment of immune system dysfunction
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
EP3407901B1 (en) 2016-01-29 2021-07-21 Massachusetts Eye & Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
WO2018111926A2 (en) 2016-12-16 2018-06-21 Inception 3, Inc. Methods of treating cochlear synaptopathy
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US12485126B2 (en) 2018-07-19 2025-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4126952A1 (en) 2020-03-26 2023-02-08 Seagen Inc. Methods of treating multiple myeloma
US20230416830A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
GEAP202516798A (en) 2022-12-14 2025-10-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802013A (en) * 1954-02-12 1957-08-06 Searle & Co 2-(oxo and imino)-3-(phenyl and halophenyl)-tetrahydrofuransulfones and processes for the manufacture thereof
US2812330A (en) * 1956-05-02 1957-11-05 Searle & Co Sulfone derivatives of 2, 6-piperidinedione
CA2191924A1 (en) * 1995-12-05 1997-06-06 Kevin Felsenstein 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
WO2001070677A1 (en) * 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
US7122675B2 (en) * 2001-08-03 2006-10-17 Schering Corporation Gamma secretase inhibitors
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
DE10201392A1 (de) 2002-01-16 2003-07-31 Bayer Ag Phenylsulfoxide und-sulfone

Similar Documents

Publication Publication Date Title
JP2006501295A5 (https=)
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP2007502806A5 (https=)
JP2024050527A5 (https=)
RU2006107653A (ru) Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли
JP2019094345A5 (https=)
ZA200107494B (en) N-cyanomethylamides as protease inhibitors.
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2005539088A5 (https=)
JP2004526680A (ja) カリウムチャネル遮断作用を有するアリール化フラン及びチオフェンカルボキサミド
JP2004514707A (ja) オルト−置換およびメタ−置換ビスアリール化合物、その製造法、医薬としてのその使用、並びにそれを含有する医薬製剤
JP2007508360A5 (https=)
JP2002513793A5 (https=)
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2003535843A5 (https=)
JP2020507589A5 (https=)
JP2006515858A5 (https=)
JPWO2023195529A5 (https=)
JP2006524222A5 (https=)
JP2004502670A5 (https=)
JP2007533722A5 (https=)
JP2007507494A5 (https=)
RU97102362A (ru) Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола
JP2020534264A5 (https=)
JP2007532627A5 (https=)